Peter A. Thompson, serving as a director at Sionna Therapeutics, Inc. (NASDAQ: SION), has reported the disposal of common stock amounting to roughly $5.27 million. The transaction, which was reported on June 30, 2026, entailed the sale of 115,844 shares at a price of $45.50 per share. This sale occurred as SION shares were currently trading at $43.99, a figure that sits below the price at which the transaction was executed. The move comes in the wake of a remarkable 99.5% return for the stock over the past year, according to InvestingPro analysis. Despite this strong performance, the analysis indicates that the stock is overvalued relative to its Fair Value, positioning it among the highly valued stocks in the market. Sionna Therapeutics, with a market capitalization of $1.88 billion, remains unprofitable, and analysts do not anticipate the company achieving profitability this year.
The securities sold by Thompson were disposed of pursuant to a Rule 10b5-1 trading plan. These shares are held indirectly by OrbiMed Private Investments VIII, LP. Thompson is a member of OrbiMed Advisors LLC, which acts as the managing member of the general partner of OrbiMed Private Investments VIII, LP. OrbiMed Advisors and its general partner have disclaimed beneficial ownership of these securities except to the extent of their pecuniary interest. Following this transaction, Thompson indirectly holds 2,555,877 shares of Sionna Therapeutics common stock.
In recent developments, Sionna Therapeutics has been the subject of several analyst updates. Stifel has maintained its Buy rating for Sionna Therapeutics, raising its price target from $44 to $55, citing confidence in the company's NBD1 data. Citizens has also reiterated a Market Outperform rating with a $63 price target, highlighting the potential of Sionna's NBD1 stabilizers for cystic fibrosis treatment. Conversely, Freedom Broker has downgraded the stock to Hold from Buy, maintaining a $38 price target, after the completion of enrollment for the SION-719 Phase 2a trial. The firm noted that upcoming readouts would address the biological risk associated with the NBD1 stabilizer mechanism.
Stifel's meetings with Sionna executives, including CEO Mike Cloonan, focused on the upcoming phase 2a proof-of-concept readout scheduled for this summer. Investors are closely watching these developments, as the data could influence future trials. The expectations from these firms reflect varied perspectives on Sionna's potential market performance. The stock currently trades at $43.99, with a 1D change of +2.35 (+5.64%), and after hours trading at $44.17, with a 1D change of +0.18 (+0.41%).